盘点:JACC11月第3期研究一览

2017-11-28 MedSci MedSci原创

1. NOACs相比华法林对房颤患者肾脏影响更小DOI: 10.1016/j.jacc.2017.09.1087终身口服抗凝药,比如华法林和非维生素K拮抗剂口服抗凝药(NOAC),被推荐用来预防房颤患者卒中的发生,最新的研究认为在肾功能影响方面NOACs可能比华法林更佳。本研究纳入了2010年十月至2016年四月开始口服抗凝药的9769名非瓣膜型房颤患者。分析结果显示,四种肾脏预后结局的2年累积发

1. NOACs相比华法林对房颤患者肾脏影响更小DOI: 10.1016/j.jacc.2017.09.1087终身口服抗凝药,比如华法林和非维生素K拮抗剂口服抗凝药(NOAC),被推荐用来预防房颤患者卒中的发生,最新的研究认为在肾功能影响方面NOACs可能比华法林更佳。本研究纳入了2010年十月至2016年四月开始口服抗凝药的9769名非瓣膜型房颤患者。分析结果显示,四种肾脏预后结局的2年累积发生风险分别为24.4%、4.0%、14.8%和 1.7%。相比于华法林,口服3种NOACs药物治疗患者的eGFR下降≥30%风险更低([HR]: 0.77; 95% [CI]: 0.66 - 0.89; p < 0.001),血清肌酐水平加倍风险更低(HR: 0.62; 95% CI: 0.40 - 0.95; p = 0.03),AKI风险也更低(HR: 0.68; 95% CI: 0.58 - 0.81; p < 0.001)。当将三种NOACs分别与华法林比较时,达比加群发生eGFR下降≥30%和AKI的风险要更低,利伐沙班发生eGFR下降≥30%、血清肌酐水平加倍和AKI风

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1853860, encodeId=e3f318538600b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Jul 24 15:07:00 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267262, encodeId=6f3e26e2628c, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Dec 06 13:46:50 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265755, encodeId=d32c265e55d6, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu Nov 30 20:51:59 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325619, encodeId=fa0f1325619eb, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Nov 30 08:07:00 CST 2017, time=2017-11-30, status=1, ipAttribution=)]
    2018-07-24 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1853860, encodeId=e3f318538600b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Jul 24 15:07:00 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267262, encodeId=6f3e26e2628c, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Dec 06 13:46:50 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265755, encodeId=d32c265e55d6, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu Nov 30 20:51:59 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325619, encodeId=fa0f1325619eb, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Nov 30 08:07:00 CST 2017, time=2017-11-30, status=1, ipAttribution=)]
    2017-12-06 虈亣靌

    不错的文章值得推荐

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1853860, encodeId=e3f318538600b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Jul 24 15:07:00 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267262, encodeId=6f3e26e2628c, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Dec 06 13:46:50 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265755, encodeId=d32c265e55d6, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu Nov 30 20:51:59 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325619, encodeId=fa0f1325619eb, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Nov 30 08:07:00 CST 2017, time=2017-11-30, status=1, ipAttribution=)]
    2017-11-30 虈亣靌

    学习了谢谢作者分享!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1853860, encodeId=e3f318538600b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Jul 24 15:07:00 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267262, encodeId=6f3e26e2628c, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Dec 06 13:46:50 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265755, encodeId=d32c265e55d6, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu Nov 30 20:51:59 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325619, encodeId=fa0f1325619eb, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Nov 30 08:07:00 CST 2017, time=2017-11-30, status=1, ipAttribution=)]
    2017-11-30 docwu2019

相关资讯

盘点:JACC10月第3期研究一览

1. 房颤致左室收缩功能不全尚未得到充分重视DOI: 10.1016/j.jacc.2017.08.041房颤和左室收缩功能不全(LVSD)常合并出现。本次多中心随机对照临床研究纳入了持续性房颤伴特发性心肌病(左室射血分数[LVEF]≤45%)的患者。患者在随机分成导管消融治疗组和药物控制组之前,接受了心脏增强磁共振检查,以评估是否存在室壁纤维瘤。导管消融包括肺静脉隔离治疗和后壁静脉隔离治疗。

JACC综述:有房颤的人胖点好?别想美事儿了!

近期,发表在JACC上的一篇综述,通过梳理大量研究很细致地探究了当前两大流行疾病肥胖和房颤之间的“纠葛”,并指出“肥胖悖论”机制不是很明确,管理体重是王道。 所谓的“肥胖悖论”,就是近来一些研究发现了一种现象:超重或肥胖的房颤患者,远期全因死亡率要比正常体重房颤患者更低。比如ORBIT-AF注册研究就显示,I级肥胖患者的全因死亡风险就比正常体重指数(BMI)房颤者降低了35%。 

盘点:JACC10月第5期一览

1. PCI术后伴复杂病变解剖结构患者的预后研究DOI: 10.1016/j.jacc.2017.09.011接受长期的双联抗血小板治疗的冠脉支架植入伴复杂病变解剖患者的风险和利益尚未阐明。本研究对25416名登记的患者和11554名随机的研究对象的心梗、支架血栓和中到重度出血事件的发现风险进行分析评估。复杂的病变解剖包括以下:无保护左主干病变,> 2 病变/血管,长度≥30毫米,分叉伴

盘点:JACC10月第4期研究一览

1. PCSK9可作为心衰患者预后的预测因子DOI: 10.1016/j.jacc.2017.08.057前蛋白转化酶枯草溶菌素9(PCSK9)可以靶向结合低密度脂蛋白受体(LDLR),防止其再循环利用。因此,PCSK9可作为动脉粥样硬化的预测因子和药物的靶点。本研究的目的是评估PCSK9-LDLR对心衰患者是否有降低动脉粥样硬化风险的作用。本研究纳入的是BIOSTAT-CHF临床试验中的心衰患者

盘点:JACC十一月第1期研究一览

1. 二尖瓣修复术的预后研究DOI: 10.1016/j.jacc.2017.09.015对于美国FDA批准通过的设备,上市后监督其有效性和安全性是必要的。本研究的目的旨在评估治疗二尖瓣反流的二尖瓣换瓣的有效性和安全性。本研究纳入分析了胸外科学会/美国心脏病学会导管治疗注册中心的二尖瓣换瓣病人的临床数据,包括2013年至2015年在145家医院接受治疗的2952名患者,其中纳入分析的有1827名患

盘点:JACC11月第2期研究一览

1. 心血管疾病风险评分--FBS vs ICHS评分DOI: 10.1016/j.jacc.2017.09.032理想心血管健康评分(ICHS)被推荐用来心血管疾病的初级预防,其他一些不需要实验室检查的更简单的工具比如福斯特BEWAT(血压[B]、运动[E]、体重[W]、营养[A]和吸烟情况[T])评分(FBS)同样也适用于初级预防评估。本研究纳入了3983例40-54岁的研究对象,亚临床动